MAUDE data represents reports of adverse events involving medical devices. This maude entry was filed from a company representative,health report with the FDA on 2020-03-27 for ZEPHYR ENDOBRONCHIAL VALVE (EBV) ZEPHYR 4.0 EBV EBV-TS-4.0 manufactured by Pulmonx Corporation.
[186541482]
Pneumothorax is the most common side effect associated with the zephyr valve treatment (criner et al. A multicenter randomized controlled trial of zephyr endobronchial valve treatment in heterogeneous emphysema (liberate). Am j respir crit care med. 2018; 198 (9): 1151-1164). Targeted lobar deflation likely causes inflation of the ipsilateral lobe, which can result in a tear of the already compromised parenchymal tissue of the emphysematous ipsilateral lobe, resulting in a pneumothorax (criner et al. A multicenter randomized controlled trial of zephyr endobronchial valve treatment in heterogeneous emphysema (liberate). Am j respir crit care med. 2018; 198 (9): 1151-1164). In the liberate study (ide clinical study used to support pma p180002's approval), 26. 6% of the zephyr valve subjects experienced a pneumothorax in the treatment period (less than or equal to 45 days). These were managed using standard of care procedures as per previously published guidelines (valipour, arschang, et al. Respiration 87. 6 (2014): 513-521). In 17. 4% of the events, the pneumothorax resolved without any additional intervention with subjects under careful observation. In over half the events (56. 5%), the pneumothorax was managed with a chest-tube only. An additional 13% of the events were managed with a chest-tube and the temporary removal of one or more valves, while another 13% of the events were managed with a chest-tube and removal of all the implanted valves. Upon successful resolution of the pneumothorax, removed valves can be replaced. Patients that experienced a pneumothorax experienced clinical benefits of the zephyr valve treatment that were similar to the benefits experienced by patients who did not have a pneumothorax. The zephyr ebv system ifu and pulmonx training program both specifically reference pneumothorax as a known side effect of this procedure and the published guidelines (valipour, arschang, et al. "expert statement: pneumothorax associated with endoscopic valve therapy for emphysema-potential mechanisms, treatment algorithm, and case examples. " respiration 87. 6 (2014): 513-521). The reported event aligns with the experience observed in the liberate clinical study and is an expected side effect to the zephyr valve treatment. All six implanted valves were eventually explanted, but it is unknown which ebv models and corresponding lots (4. 0 ebv lot# 504441-v7. 0, 4. 0 ebv lot# 504619-v7. 0, 5. 5 ebv lot# 504257-v7. 0) were explanted on which dates. Four of the six implanted valves were explanted on feb. 26, 2020, and the remaining two implanted valves were explanted on mar. 17, 2020.
Patient Sequence No: 1, Text Type: N, H10
[186541483]
On (b)(6) 2020, patient underwent bronchoscopic lung volume reduction with six zephyr endobronchial valves (4. 0 ebv, 5. 5 ebv) placed in the right lower lobe. On (b)(6) 2020, the patient developed a pneumothorax, and the interventional radiology team placed a 12 fr chest tube. On (b)(6) 2020, four of the six implanted valves were removed. On (b)(6) 2020, the pneumothorax still had not resolved, so the 12 fr chest tube was replaced with a 14 fr chest tube, which drained everything. Patient was then discharged from the hospital to a long term acute care facility. On (b)(6) 2020, the remaining two implanted valves were removed, and the chest tube was removed the next day. On (b)(6) 2020, patient was discharged home.
Patient Sequence No: 1, Text Type: D, B5
| Report Number | 3007797756-2020-00077 |
| MDR Report Key | 9889106 |
| Report Source | COMPANY REPRESENTATIVE,HEALTH |
| Date Received | 2020-03-27 |
| Date of Report | 2020-03-27 |
| Date of Event | 2020-02-28 |
| Date Mfgr Received | 2020-02-26 |
| Device Manufacturer Date | 2019-07-11 |
| Date Added to Maude | 2020-03-27 |
| Event Key | 0 |
| Report Source Code | Manufacturer report |
| Manufacturer Link | Y |
| Number of Patients in Event | 0 |
| Adverse Event Flag | 3 |
| Product Problem Flag | 3 |
| Reprocessed and Reused Flag | 3 |
| Health Professional | 3 |
| Initial Report to FDA | 3 |
| Report to FDA | 3 |
| Event Location | 3 |
| Manufacturer Contact | MS. LELAND KEYT |
| Manufacturer Street | 700 CHESAPEAKE DRIVE |
| Manufacturer City | REDWOOD CITY, CA |
| Manufacturer Country | US |
| Manufacturer Phone | 2160144 |
| Single Use | 3 |
| Remedial Action | PM |
| Previous Use Code | 3 |
| Event Type | 3 |
| Type of Report | 3 |
| Brand Name | ZEPHYR ENDOBRONCHIAL VALVE (EBV) |
| Generic Name | ENDOBRONCHIAL VALVE |
| Product Code | NJK |
| Date Received | 2020-03-27 |
| Model Number | ZEPHYR 4.0 EBV |
| Catalog Number | EBV-TS-4.0 |
| Lot Number | 504441-V7.0 |
| Operator | HEALTH PROFESSIONAL |
| Device Availability | N |
| Device Eval'ed by Mfgr | N |
| Device Sequence No | 1 |
| Device Event Key | 0 |
| Manufacturer | PULMONX CORPORATION |
| Manufacturer Address | 700 CHESAPEAKE DRIVE REDWOOD CITY, CA US |
| Patient Number | Treatment | Outcome | Date |
|---|---|---|---|
| 1 | 0 | 1. Hospitalization; 2. Required No Informationntervention | 2020-03-27 |